乙型病毒性肝炎的诊断技术与药物治疗研究进展

Advances in Diagnostic Technique and Pharmacological Therapy of Hepatitis B

乙型病毒性肝炎(HB)是临床上常见的疾病,由乙型肝炎病毒(HBV)感染而引起,在我国发病率较高。HB会造成不同程度的肝功能损害,严重者将造成肝功能衰竭、肝硬化甚至肝细胞癌,威胁患者的生命。因此,HB患者的早期诊断和治疗,在避免肝功能损害、提高生存期和改善预后方面具有重要的意义。目前HB的治疗以聚乙二醇干扰素(Peg-INF)和核苷酸类似物(NUC)为代表的抗病毒药物为主。虽然这些传统药物可以抑制HBV复制,延缓肝功能受损,但无法彻底清除病毒。随着医疗技术的发展,越来越多的检测技术和新型药物应用于HB患者的诊断与治疗,并取得了良好的临床效果。本文就近年来HB诊断技术与药物治疗的进展进行综述,旨在为HB的临床诊治及未来研究提供参考。

Hepatitis B (HB) is a prevalent disease in clinical practice with highly incidence in China, which is caused by hepatitis B virus (HBV) infection. HB could leads to liver damage progressing as liver cirrhosis, liver failure or even hepatocellular carcinoma (HCC) and threats to life in HB patients. Thus, early detection, diagnosis and treatment play a vital part in improving the prognosis and enhancing the survival of HB patients. In recent years, treatment of HB is dominated by two groups of agents: Pegylated interferons (IFN) and nucleostide analogs (NUC). Though these traditional medicines could improve liver function and inhibit HBV replication, they fail to establish a functional cure. Due to the development of medical technology, more and more advanced techniques and drugs has been developing, some of which were launched for clinical use and sachieved brilliant results. Therefore, this review focus on the recent progress in our understanding of diagnostic techniques and therapeutic agents for HB, which intends to provide references for clinical management and further scientific research.